Safety Study of Inhaled Saline in Acute Lung Injury
NCT01713595 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2015-08-17
Summary
To determine if an inhaled hypertonic saline solution has any effect on lung function in patients with acute respiratory distress syndrome (ARDS).
Conditions
- Pulmonary Edema
Interventions
- DRUG
-
Hypertonic Saline Aerosol
A single 5ml dose of 7% Saline aerosol
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Richard A Oeckler, M.D., Ph.D. · Mayo Clinic
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-10-31
- Primary Completion
- 2015-05-31
- Completion
- 2015-05-31
More Related Trials
-
Effect of Nebulized and Intravenous Hypertonic Saline 3% on the Management of Patients With Acute Respiratory Distress Syndrome
NCT06226402 ·Status: RECRUITING ·Phase: NA
-
Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury
NCT01627613 ·Status: COMPLETED ·Phase: PHASE2
-
Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS
NCT03465085 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of ARDS With Instilled T3
NCT04115514 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Extension of the RUSH Protocol for Volume Responsiveness
NCT03285269 ·Status: WITHDRAWN
-
Hypertonic Modulation of Inflammation Following Injury
NCT00750997 ·Status: TERMINATED
-
Calfactant for Direct Acute Respiratory Distress Syndrome
NCT00682500 ·Status: TERMINATED ·Phase: PHASE3
-
Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)
NCT00000579 ·Status: COMPLETED ·Phase: PHASE3
-
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
NCT04493242 ·Status: COMPLETED ·Phase: PHASE2
-
Hypertonic Resuscitation Following Traumatic Injury
NCT00316017 ·Status: TERMINATED ·Phase: PHASE3
-
A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure
NCT04319731 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Nebulized Furosemide, Heparin, Hypertonic Saline in Mechanically Ventilated Acute Respiratory Distress Syndrome Adult Patients
NCT07286409 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS
NCT03567577 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Fluid Resuscitation and Microcirculation
NCT01369524 ·Status: COMPLETED
-
Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia
NCT04609865 ·Status: TERMINATED ·Phase: PHASE3
-
KL₄Surfactant Treatment in Patients With ARDS
NCT00215553 ·Status: TERMINATED ·Phase: PHASE2
-
Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma
NCT01411852 ·Status: COMPLETED ·Phase: PHASE2
-
Hypertonic Saline Resuscitation in Trauma Patients After Hemorrhage Control
NCT02542241 ·Status: TERMINATED ·Phase: PHASE4
-
Resuscitation Fluid Choice and Clinical Outcomes
NCT02641119 ·Status: COMPLETED
-
Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in Patients With ARDS
NCT05241067 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Prospective Observational Study of the Expectations and Physiological Effects of Fluid Bolus Therapy
NCT03178578 ·Status: UNKNOWN
-
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05354141 ·Status: RECRUITING ·Phase: PHASE3
-
"Effects of Neuromuscular Blocking Agents on End Expiratory Lung Volume During Moderate-severe ARDS"
NCT04996394 ·Status: COMPLETED
-
Nebulised Rt-PA for ARDS Due to COVID-19
NCT04356833 ·Status: COMPLETED ·Phase: PHASE2
-
Fluid Mobilization in Hospitalized Patients With Acute Kidney Injury
NCT04522635 ·Status: COMPLETED ·Phase: PHASE4